ArticleJAMA network open2023

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.

Mehul Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.